Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment.
John Radcliffe Hospital, Oxford, UK. jeremy.hull@paediatrics.ox.ac.uk
Jeremy
J
Hull
D000627:Aminophenols / Q000494:pharmacology / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D018388:Codon, Terminator / Q000187:drug effects; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000187:drug effects* / Q000235:genetics; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005544:Forecasting; D005786:Gene Expression Regulation; D020022:Genetic Predisposition to Disease / Q000453:epidemiology; D006801:Humans; D017136:Ion Transport / Q000187:drug effects; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods*; D009154:Mutation; D020380:Needs Assessment; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D015222:Sodium Channels / Q000187:drug effects
D000627:Aminophenols; D018388:Codon, Terminator; D015507:Drugs, Investigational; D015363:Quinolones; D015222:Sodium Channels; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C545203:ivacaftor